Telix Pharmaceuticals (TLX) Stock Price, News & Analysis

Company Overview

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates. Its lead product for prostate cancer imaging, Illuccix® (TLX591-CDx), is a kit-based gallium-68 PSMA agent designed to simplify PET scan preparation in decentralized nuclear medicine settings. Telix is also advancing PSMA-targeted therapy using lutetium-177, as well as somatostatin receptor-directed compounds for neuroendocrine tumors. Other programs in earlier stages include radiolabeled antibodies and small molecules aimed at bladder, brain and renal cancers.

Headquartered in Melbourne, Australia, Telix maintains commercial and clinical operations across North America, Europe and Asia Pacific. The company has secured regulatory approvals and reimbursements in multiple regions for its imaging products, and is conducting pivotal trials in the U.S. and Europe to expand patient access. Telix collaborates with leading academic institutions and contract research organizations to support its global clinical development and aims to build a scalable manufacturing and distribution network for radiopharmaceuticals.

Since its founding in 2015, Telix has grown under the leadership of CEO Dr. Christian Behrenbruch, who brings experience in healthcare management and specialized radiopharmaceutical development. The management team combines expertise in drug development, nuclear medicine and commercial operations. Telix continues to explore strategic partnerships and licensing agreements to accelerate the adoption of targeted radiopharmaceuticals and establish a new standard of care for oncology patients.

Key Stats

• Today's Range: $11.62 to $11.77
• 50-Day Range: $9.58 to $12.42
• 52-Week Range: $6.28 to $12.58
• Volume: 34,126 shs
• Average Volume: 196,717 shs
• Market Capitalization: $3.96 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.40
• Consensus Rating: Moderate Buy

Telix Pharmaceuticals Stock Analysis - MarketRank™

Telix Pharmaceuticals scored higher than 77% of companies evaluated by MarketBeat, and ranked 130th out of 917 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Telix Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 4 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

Telix Pharmaceuticals has a consensus price target of $20.40, representing about 74.9% upside from its current price of $11.67.

Amount of Analyst Coverage

Telix Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -14.29%

Earnings Growth

Earnings for Telix Pharmaceuticals are expected to decrease by -14.29% in the coming year, from $0.07 to $0.06 per share.

Price to Book Value per Share Ratio

Telix Pharmaceuticals has a P/B Ratio of 9.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.08% of the float of Telix Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Telix Pharmaceuticals has a short interest ratio ("days to cover") of 2.56, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Telix Pharmaceuticals has recently decreased by 6.55%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Telix Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Telix Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.44

News Sentiment

Telix Pharmaceuticals has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Telix Pharmaceuticals this week, compared to 9 articles on an average week.

Search Interest

Only 3 people have searched for TLX on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Telix Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Institutions

Telix Pharmaceuticals has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 2/20/2026
• Today: 8/25/2026
• Investor Day 2026: 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TLX
• Previous Symbol: NASDAQ:TLX
• CIK: 2007191
• Web: www.telixpharma.com
• Phone: 61-3-9093-3855
• Fax: N/A
• Employees: 1,184
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Telix Pharmaceuticals: $20.40
• High Price Target: $22.00
• Low Price Target: $18.00
• Potential Upside/Downside: +74.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 1.16
• Current Ratio: 2.01
• Quick Ratio: 1.85

Sales & Book Value

• Annual Sales: $803.79 million
• Price / Sales: 4.94
• Cash Flow: $0.04 per share
• Price / Cash Flow: 268.72
• Book Value: $1.23 per share
• Price / Book: 9.50

Miscellaneous

• Outstanding Shares: 339,780,000
• Free Float: N/A
• Market Cap: $3.97 billion
• Optionable: N/A
• Beta: -0.24